Last updated: July 29, 2026
Peptides for horses are the oldest branch of veterinary peptide use — older than the human biohacking market that made these compounds famous. Equine practices have been using TB-500 for tendon and ligament injury since the early 2000s, which gives equine use the longest real-world track record of any species.
The reason is straightforward. Tendon injuries end careers, tendon tissue heals slowly because its blood supply is poor, and a peptide whose primary action is angiogenesis addresses exactly that limitation. This guide covers what is used, dosing for a 500 kg animal, gastric ulcers, and the competition rules that dog and cat owners never have to think about.
Quick Answer: Peptides in Horses
- TB-500 is the first-line choice for tendon and ligament injury, not BPC-157. It has the longest equine track record and stimulates tenocyte proliferation directly.
- BPC-157 is the choice for gastric ulcers (EGUS) and for soft-tissue and wound work, often stacked with TB-500.
- Dosing is bodyweight-scaled like every species, but at 500 kg the absolute quantities are large — a 5 mcg/kg dose is 2,500 mcg, so vial economics look completely different.
- Check competition rules before you dose anything. Regulations differ between FEI, national federations and racing commissions, and they change.
- Nothing here is approved for horses. Use is off-label and grey-market, and in performance horses the regulatory exposure is real.
Why Equine Use Came First
Sport-dog and equine practices were using BPC-157, TB-500, oxytocin and GnRH agonists routinely for tendon, mucosal, reproductive and behavioural indications years before the human wellness market discovered them. The economics explain it: a performance horse represents a large investment, tendon injuries are common and career-ending, and conventional treatment options for a bowed tendon are limited and slow.
The clinical problem is specific. Tendon is poorly vascularised, which is why it heals slowly and why the repair tissue is often mechanically inferior to what it replaced. Any intervention that improves blood supply to healing tendon is attacking the actual bottleneck rather than the symptoms.
TB-500 for Horses
TB-500 is a synthetic fragment of thymosin beta-4, a protein central to tissue repair. It works through actin sequestration and cell migration, and research indicates it stimulates tenocyte proliferation and collagen production — the specific cellular processes tendon repair depends on. It also promotes angiogenesis, which addresses the blood supply problem directly.
Equine applications:
- Superficial digital flexor tendon injury — the classic bowed tendon, and the injury TB-500 is most associated with.
- Suspensory ligament desmitis — both branch and body lesions.
- Deep digital flexor tendon lesions.
- Muscle tears and general soft-tissue trauma.
Published veterinary research favours TB-500 over BPC-157 specifically for tendon and ligament work, which is the reverse of the ordering in dogs. Dosing is less frequent than daily — loading schedules of twice weekly followed by weekly maintenance are typical, reflecting the peptide's longer tissue residence. See TB-500 side effects for the safety profile.
BPC-157 for Horses
BPC-157 earns its place in equine practice for two distinct reasons.
Gastric ulcers. Equine gastric ulcer syndrome is extraordinarily common in performance horses — a consequence of stall confinement, concentrate feeding, intermittent forage access and training intensity. BPC-157 was originally characterised as a gastroprotective peptide derived from gastric juice, and mucosal protection and repair is its most direct application. For a horse on omeprazole with recurring ulceration after withdrawal, this is the most compelling indication in the species.
Soft tissue and wounds. Angiogenesis, VEGF signalling and reduced inflammation apply here as in every species. It is frequently run alongside TB-500 for significant tendon injury, since the two act on different pathways.
Dosing for a 500 kg Horse
The mcg/kg logic is the same as every other species; the absolute numbers are what change. At 500 kg, a 5 mcg/kg dose is 2,500 mcg — 2.5 mg, or a quarter of a standard 10 mg vial in a single dose.
Administration is intramuscular or subcutaneous. Injection volumes are meaningful rather than the fractions of a millilitre used in cats, which makes accurate dosing considerably easier. Standard equine injection sites and technique apply, and this is work for someone competent with equine injections.
GHK-Cu, Wounds and Proud Flesh
GHK-Cu occupies a smaller but genuine niche in equine practice. Horses are exceptionally good at injuring themselves on fencing, and distal limb wounds are notoriously difficult: minimal soft tissue coverage, poor blood supply, constant movement across the wound bed, and a strong tendency toward exuberant granulation tissue — proud flesh.
GHK-Cu drives collagen and elastin synthesis and shifts gene expression toward an organised repair phenotype rather than disordered granulation. That is the theoretical argument for using it on lower limb wounds, and it applies topically as well as systemically, which sidesteps both the cost and the regulatory exposure of injecting a large animal.
It is also used in scar remodelling after wounds have closed and as an adjunct in surgical incision healing. The copper load that warrants caution in a small cat is a non-issue at equine bodyweight.
Fitting Peptides Into a Rehabilitation Programme
The most common mistake in equine peptide use is treating the peptide as the programme rather than as one input into it. Tendon outcomes are determined by graded loading and imaging-led reassessment, and no peptide changes that.
Where peptides fit, roughly:
The honest summary is that a peptide may improve the quality of the healing environment during the repair and remodelling phases. It does not license bringing a horse back sooner, and horses returned to work early on the strength of feeling better re-injure at the same rates they always have.
Competition Rules: Read This Before You Dose
This is the section with no equivalent in the dog and cat guides, and it is the one that costs people the most.
Regulatory status varies by governing body and changes over time. BPC-157 was added to the WADA prohibited list in 2022 and its status has since shifted; that is the human anti-doping framework, and it is not the framework that governs your horse. What governs your horse is the FEI, your national federation, or the relevant racing commission — and each maintains its own prohibited substances list with its own detection thresholds and withdrawal guidance.
Points worth being explicit about:
- Check the current list, not a summary. These lists are revised, and an article — this one included — is not a substitute for the governing body's published rules on the day you compete.
- There is no published withdrawal time for compounds that are not approved veterinary medicines. Absence of a stated withdrawal period is not the same as absence of detection risk.
- Testing capability moves. A compound not routinely screened for today may be screened for next season, and samples can be stored.
- Responsibility sits with the person responsible under FEI rules regardless of who administered what.
For a horse in active competition, the honest position is that using unapproved peptides carries regulatory risk that cannot be eliminated by timing. For a horse out of competition on a rehabilitation programme, that calculus is entirely different.
Legality and Safety
No peptide discussed here is approved for use in horses. Compounded animal drugs made from bulk substances are unapproved drugs, though FDA guidance GFI #256 sets out conditions under which the agency does not intend to take enforcement action. In July 2026 an FDA advisory committee voted narrowly in favour of allowing compounding pharmacies to prepare BPC-157, KPV, TB-500 and MOTS-c — a non-binding recommendation aimed at human compounding, but one that shifts the broader picture. The peptides for animals overview covers the regulatory position in full.
On safety, the same angiogenesis caution applies: these peptides promote blood vessel growth, which argues against use in an animal with a known or suspected neoplasm. Vendor quality is the other live issue, and it matters more at equine doses simply because of the quantity involved. Buy from suppliers publishing third-party certificates of analysis that name the batch and the testing laboratory — our TB-500 sourcing guide covers who actually tests.
Peptides are an adjunct to a rehabilitation programme, not a replacement for one. Controlled exercise progression, imaging-led reassessment and appropriate rest remain what determines whether a tendon injury resolves. A peptide that improves the healing environment does nothing for a horse brought back to work too early.
For the small-animal picture, see peptides for dogs and peptides for cats.
